Core Viewpoint - The article emphasizes the importance of international biological cooperation for resource integration and technological sharing, while highlighting the potential risks associated with the loss of human genetic resources and core research data, which could pose significant threats to national security [1] Group 1: Biological Data Security Risks - Biological data may become a "biological bomb" as foreign entities could exploit "academic cooperation" or "public projects" to obtain unapproved biological samples from domestic institutions, potentially leading to the loss of valuable biological samples that could impact gene patents and biopharmaceuticals [2] - The leakage of genetic data poses a crisis as it can be used to analyze the health status, genetic weaknesses, and population structure of the Chinese population, creating a "biological map" that could aid in the development of targeted biotechnologies [2] - Research in biology heavily relies on information technology and automation, with equipment from foreign companies potentially containing "backdoors" that could serve as hidden channels for data theft, threatening the security of biological research data [2] Group 2: Prevention of Biological Data Security Risks - The "Biological Safety Law of the People's Republic of China" imposes strict regulations on the collection and preservation of human genetic resources, prohibiting foreign organizations from obtaining or providing these resources without prior approval from relevant authorities [3] - International scientific research cooperation involving Chinese biological resources must ensure substantial participation from Chinese entities and researchers, with legal sharing of related rights [3] Group 3: National Security Agency Alerts - The security of biological data is crucial for national security, necessitating that international biological cooperation and cross-border data transmission be conducted in accordance with laws and regulations [4] - Industry professionals are urged to resist illegal data sharing and remain vigilant against foreign entities that may disguise data theft as research collaboration [4] - The public and researchers are encouraged to report any suspicious activities related to biological data leakage or illegal sample transfers that may threaten national security [4]

Core Viewpoint - The FDA has announced a new regulation that requires all imported products to undergo review, regardless of their value or size, following the cancellation of the small package exemption policy [2][3][4]. Group 1: Regulatory Changes - The previous exemption for products valued under $800 has been eliminated, meaning all products will now be subject to full review [3]. - This policy took effect on July 9 and aims to enhance the FDA's oversight of the U.S. supply chain and improve the identification of repeat violators [4]. - The new regulation applies to all product categories regulated by the FDA, including drugs, food, beverages, dietary supplements, cosmetics, medical devices, and biological samples [6]. Group 2: Impact on Imports - The FDA can now review all imported products declared through electronic systems, including those purchased online and transported across borders [5]. - Even small packages must adhere to the same regulatory standards as larger shipments, which may affect the circulation of weight-loss drugs in the "gray market" [8]. - A study indicated that in January, shipments of active ingredients from unregistered Chinese suppliers increased by 44% compared to the previous month [8]. Group 3: Implications of the Policy - The data does not account for packages that previously entered the U.S. under the exemption policy, suggesting that the actual import volume may be significantly higher than current statistics indicate [9]. - This policy adjustment is part of the FDA's efforts to close regulatory loopholes and strengthen comprehensive import reviews [10].